Nureca LimitedQ1 FY27 Results & Financial Update
Nureca Limited: Q1 FY27 consolidated results and company financials – revenue ₹40.34 Cr, PAT ₹3.07 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Nureca price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Nureca Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
The operational turnaround initiated in the preceding financial year carried forward into Q1 FY27, driven by disciplined cost management and ongoing category expansion across both online and offline distribution channels.
Gross margins remained stable at 38.8%, reflecting steady product realization and balanced segment contributions across the company's home healthcare portfolio.
The company maintained a debt-free balance sheet with robust liquidity, reporting net cash and investments of approximately ₹110 crore as of June 30, 2026.
Management highlighted that domestic manufacturing continues to serve as a cornerstone for long-term strategy, offering supply-chain control and import substitution while expanding local production capabilities in Punjab.
Profit after tax was ₹3.07 Cr for the reported quarter. EPS was ₹3.21 for the reported quarter.
01 · Business model
What does Nureca do?
Nureca Limited operates as a digital-first and omnichannel consumer healthcare platform in India, specializing in home healthcare, wellness, and personal-care categories under well-established consumer brands such as Dr Trust, Dr Physio, and Trumom.
The company's product architecture spans seven core ranges across the home-health journey, including point-of-care vital monitors, chronic care devices, fitness metrics, massage-led pain relief, heat therapy, orthopedic supports, and mother-and-baby care products.
Distribution is executed through an omnichannel framework spanning online marketplaces, quick commerce, direct-to-consumer digital channels, and an extensive offline retail network covering over 20,000 pharmacies supported by super stockists and distributors.
Nureca integrates its physical hardware with a connected-health ecosystem anchored by the Dr Trust 360 application, which links smart devices, health data, and AI-powered personalized insights to deepen user engagement.
02 · Historical context
What shaped the business before this quarter
Nureca was founded in 2016 with the digital launch of Dr Trust, subsequently expanding its brand portfolio with the introduction of Dr Physio and Trumom in 2018.
The company launched the Dr Trust 360 connected device ecosystem in 2020 and successfully completed its initial public offering on the NSE and BSE in 2021.
Nureca commenced domestic manufacturing operations in 2022 under subsidiary NTPL, achieving ISO 9001 and ISO 13485 quality certifications.
The company expanded its retail footprint to over 20,000 offline pharmacies and integrated quick commerce delivery channels alongside securing a 'Well Known Trademark' for Dr Trust.
USFDA registration was completed for the Mohali facility in 2025, followed by construction initiation for a new medical device plant at Sundran, Punjab, and the Dr Trust 360 app surpassing 2 million users in 2026.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹40.34 Cr |
| Total income | ₹42.16 Cr |
| Profit before tax | ₹4.43 Cr |
| Profit after tax | ₹3.07 Cr |
| EPS | ₹3.21 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Ecommerce and digital marketplace sales grew by 16% year-on-year and 5% sequentially, supported by category expansion and sustained demand across existing product lines.
The offline retail network achieved significant expansion, with revenue trending up 57% year-on-year and 14% quarter-on-quarter as distribution coverage widened through super stockists and new channel partners.
Total gross merchandise value reached ₹51.8 crore for Q1 FY27, compared to ₹49.7 crore in Q4 FY26.
What drove margins
Gross margin was sustained at 38.8% for the quarter (noted as 39% in presentation rounding), showing a minor 6 basis point increase year-on-year.
Disciplined expense management kept total expenses at ₹36.9 crore for the quarter, allowing operating profit to expand to ₹3.42 crore (8.5% operating margin).
05 · Demand, customers & order book
Where demand is coming from
The Dr Trust 360 app user base expanded to 2.4 million users, with the application ranking among the Top 50 Health & Fitness apps on the iOS store.
Offline distribution extends to over 20,000 retail pharmacies across India.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Operations spanned across Dr Trust Point of Care, Dr Trust Fitness, Dr Physio (massage therapy), Dr Trust Therapy & Recovery, Dr Trust Orthotics, Trumom Mother & Baby, and Dr Trust Healthy Home.
Geography and market mix
Operations remain anchored in the Indian market, supported by the recent launch of the Dr Trust 360 app in Nepal and participation in the broader domestic home healthcare products market.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The existing manufacturing facility in Mohali, Punjab (Nureca Technologies Private Limited) provides an annual capacity of 8 lakh units, holding 15 CDSCO approvals, ISO 9001:2015, ISO 13485:2016, and USFDA registrations.
In-house manufactured products accounted for 27% of total revenue in Q1 FY27, compared to 26% for the full year FY26.
Projects, capex and execution
Construction commenced on a new dedicated medical device manufacturing facility at Sundran, Punjab, intended to deepen supply-chain control, drive import substitution, and scale production in medical devices, consumables, and hygiene products.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The Dr Trust 360 platform was enhanced with AI-powered health insights, introducing trend detection and automated summaries to increase user engagement across smart scales, blood pressure monitors, and kitchen scales.
09 · Reported developments
What changed operationally
The company achieved its highest quarterly sales and profitability performance in 16 quarters, marking the strongest period since Q4 FY22.
Net cash and investments stood at ₹110 crore, ensuring strong liquidity to fund ongoing manufacturing expansion projects.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
Nureca reported zero bank debt alongside a robust cash and investment reserve of ₹110 crore as of June 30, 2026.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
Brand Ambassador Engagement
Cricketer Rohit Sharma continues to serve as the brand ambassador for Dr Trust, supporting marketing initiatives across digital and offline channels.
12 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations increased by 14% quarter-on-quarter from ₹35.4 crore in Q4 FY26 to ₹40.34 crore in Q1 FY27.
13 · Key Q&A
The quarter, answered directly
What does Nureca do?
Nureca Limited operates as a digital-first and omnichannel consumer healthcare platform in India, specializing in home healthcare, wellness, and personal-care categories under well-established consumer brands such as Dr Trust, Dr Physio, and Trumom.
What is the clearest takeaway from Q1 FY27?
The operational turnaround initiated in the preceding financial year carried forward into Q1 FY27, driven by disciplined cost management and ongoing category expansion across both online and offline distribution channels.
What drove revenue or demand?
Ecommerce and digital marketplace sales grew by 16% year-on-year and 5% sequentially, supported by category expansion and sustained demand across existing product lines.
What mattered most for margins or profitability?
Gross margin was sustained at 38.8% for the quarter (noted as 39% in presentation rounding), showing a minor 6 basis point increase year-on-year.
What changed operationally beyond the headline numbers?
The existing manufacturing facility in Mohali, Punjab (Nureca Technologies Private Limited) provides an annual capacity of 8 lakh units, holding 15 CDSCO approvals, ISO 9001:2015, ISO 13485:2016, and USFDA registrations.
What should the next disclosure help confirm?
Track the proportion of revenue generated from in-house manufactured goods relative to outsourced inventory as Punjab capacity scales.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
In-House Manufacturing Share: Track the proportion of revenue generated from in-house manufactured goods relative to outsourced inventory as Punjab capacity scales.
- 02
Digital App User Growth: Observe user acquisition metrics and engagement levels for the Dr Trust 360 connected health ecosystem following AI feature integrations.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.